卢旺达恶性疟原虫K13突变高流行与蒿甲醚-苯芴醇治疗后虫体清除延迟相关
2018至2019年在马里、加蓬、加纳、乌干达和卢旺达开展2期临床研究,186例疟疾患者随机接受蒿甲醚-苯芴醇或cipargamin治疗。卢旺达R561H等位基因频率达22%,与虫体清除延迟相关,但蒿甲醚-苯芴醇校正治愈率仍为94.4%。
要点
- 卢旺达恶性疟原虫K13 R561H等位基因频率为22%。
- R561H与蒿甲醚-苯芴醇治疗后虫体清除延迟相关。
- 卢旺达蒿甲醚-苯芴醇PCR校正治愈率仍达94.4%。
核心结论
- 卢旺达K13 R561H突变频率较高,并与蒿甲醚-苯芴醇治疗后虫体清除延迟相关,但该药疗效仍较高。
研究设计与样本
- 2018至2019年在马里、加蓬、加纳、乌干达和卢旺达开展的2期临床研究,共纳入186例疟疾患者。
- 患者随机接受蒿甲醚-苯芑醇或cipargamin治疗。
主要发现
- 卢旺达R561H等位基因频率为22%。
- R561H与虫体清除延迟相关。
- 卢旺达蒿甲醚-苯芑醇PCR校正治愈率为94.4%。
关键数值与推荐
- R561H等位基因频率:22%(卢旺达)。
- 蒿甲醚-苯芑醇PCR校正治愈率:94.4%(卢旺达)。
临床怎么用
- 在卢旺达及周边地区应关注K13 R561H突变流行情况。
- 蒿甲醚-苯芑醇在该研究中仍保持较高治愈率,但需监测虫体清除延迟。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In Southeast Asia, mutations in the Plasmodium falciparum K13 gene have led to delayed parasite clearance and treatment failures in patients with malaria receiving artemisinin combination therapies. Until recently, relevant K13 mutations had been mostly absent from Africa. Between 2018 and 2019, a phase 2 clinical study with 186 patients was conducted in Mali, Gabon, Ghana, Uganda, and Rwanda. Patients with malaria were randomized and treated with artemether-lumefantrine or cipargamin. Here we report an allele frequency of 22% for R561H in Rwanda and associated delayed parasite clearance. Notwithstanding, efficacy of artemether-lumefantrine remained high in Rwanda, with a 94.4% polymerase chain reaction-corrected cure rate.
引用
- Straimer J, Gandhi P, Renner KC, et al. High Prevalence of Plasmodium falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine. J Infect Dis. 2022. PMID: 34216470. doi:10.1093/infdis/jiab352
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。